Orchid Pharma Limited — Board Meeting, 12-08-2025: Outcome of Board Meeting

Orchid Pharma's board has announced a meeting outcome, approving the financial results for the quarter ended June 30, 2025. Consolidated net sales stood at ₹172.93 Cr, with profit reaching ₹14.91 Cr. Basic EPS for the quarter was ₹2.94. The board also approved the appointment of Internal, Cost, and Secretarial Auditors for FY2025-26, with the Secretarial Auditor appointed for five years, subject to shareholder approval. The company continues to progress its amalgamation scheme with Dhanuka Laboratories, with NCLT admitting the petition. The Annual General Meeting is set for September 20, 2025, with e-voting from September 17-19.